NSCLC Treatment - Recurrent or Refractory Disease
	Second-line Treatment
	Additional Treatment Options

Second-line Treatment

Second-line Weekly Paclitaxel in Patients with Inoperable NSCLC Who Fail Combination Chemotherapy With Cisplatin (PubMed)
Phase II study published in the August issue of Lung Cancer that found second-line treatment with single-agent paclitaxel is well-tolerated, active and associated with long survivals in inoperable NSCLC patients whose disease does not respond or recurs following standard front-line platinum-based chemotherapy. [8/04]

Second-line Treatment - Recent MEDLINE Abstracts (PubMed)

Additional Treatment Options

Third-line Treatment - Recent MEDLINE Abstracts (PubMed)

"Salvage" Treatment - Recent MEDLINE Abstracts (PubMed)